PNEUMOLOGIE呼吸病学
PNEUMOLOGIE(英文缩写 PNEUMOLOGIE),ISSN 0934-8387,eISSN 1438-8790,中文译名:呼吸病学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 未收录 | N/A |
| 2022 | 1.200 | N/A |
| 2023 | 1.200 | Q4 |
| 2024 | 1.700 | Q3 |
| 2025 | 1.000 | Q4 |
PNEUMOLOGIE 最新收录文献
-
1. [Follow-up after lung transplantation: a complex and interdisciplinary task].
PMID:日期:2026-09-01Follow-up of lung transplant patients is complex and requires highly specialized and interdisciplinary collaboration both in inpatient and outpatient settings. A structured approach became available in Germany, Austria and Switzerland when the first guideline for the follow-up care of lung transplant recipients was published in 2025.Regular follow-up intends to prevent or detect allograft dysfunction at an early stage. Bronchopulmonary infections, acute or chronic rejection and airway complications are the main causes of allograft dysfunction. This has to be considered in diagnostic pathways.Furthermore, it is essential to closely monitor possible toxicities and long-term side effects of immunosuppressive medication. These toxicities include renal insufficiency, diabetes mellitus, osteoporosis, arteriosclerosis, chronic infection and the development of malignant neoplasm.
-
2. [Myositis and NSCLC: an interdisciplinary case report].
PMID:日期:2026-09-01Rheumatological diseases such as myositis might be detected during the diagnostic process of lung cancer.This suggests the need for interdisciplinary dialogue concerning thoracooncological and immunosuppressive treatment of myositis and associated interstitital lung diseases. In particular, the side effects of checkpoint inhibitors must be taken into consideration.This case report is about the detection of myositis-associated interstitial lung disease in the course of a thoracooncological treatment regimen.
-
5. [Documentation of biological treatment in asthma].
PMID:日期:2026-09-01Biologics are the first-line treatment for patients with severe, poorly controlled asthma and can lead to a significant reduction (or even complete avoidance) of exacerbations and the need for systemic corticosteroids - which are associated with numerous side effects - as well as to a marked improvement in asthma control and lung function in severe asthma. Due to the high annual costs of biologic therapy, there is a legitimate interest on the part of payers in the cost-effective use of biologics for severe asthma in accordance with guidelines and regulatory approvals; conversely, there is a legitimate interest on the part of treating physicians in prescribing these biologics in a manner that protects them from liability claims. In an analysis of the literature and regulatory approvals, combined with the experience of the participating authors, evidence was compiled regarding therapy with the biologics approved for severe asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, and depemokimab. Based on guideline recommendations and approvals, recommendations are provided for the use of the aforementioned biologics within the German healthcare system. In a joint effort by various professional societies (AeDA, DGP, BdP, GAN, DGAKI, GPP, GPA), documentation forms were created for all biologics approved for severe asthma, which can serve as a basis for documentation. Forms were developed both for initiating biologic therapy and for documenting the course of biologic therapy in severe asthma. The new documentation forms provide a practical, one-page summary of all key points regarding the prescription of biologics and the assessment of response to biologics in severe asthma, serving both to ensure prescribing in accordance with guidelines and regulatory requirements and to prevent drug-related claims.
-
6. [Differences between women and men in rheumatic systemic diseases with lung involvement].
PMID:日期:2026-09-01Biological sex has a significant impact on the prevalence and course of lung involvement and inflammatory rheumatic diseases (IRD). However, data and analyses addressing this relationship are lacking for Germany. In a retrospective analysis, data from the German Federal Statistical Office were evaluated using hospital discharge diagnoses coded according to the International Classification of Diseases (ICD-10) from 2005 to 2023. Frequency, temporal trends, and distribution were analysed separately for women and men. Eleven rheumatologic diseases as primary diagnoses were included: rheumatoid arthritis (M05, M06), connective tissue diseases (M32-M35), and ANCA-associated vasculitis (M30.1, M31.3, M31.7). Each was combined with five secondary diagnoses indicating pulmonary involvement (J84.1, J84.8, J84.9, J99.0*, J99.1*). Over the 19-year observation period, the total number of hospitalizations for women with IRD (n = 734,167; 68%) exceeded that of men (n = 349,806; 32%). The absolute number of cases with lung involvement associated with IRD was also higher in women (n = 88,936) than in men (n = 52,523). However, the relative proportion of lung involvement among patients with IRD was higher in men compared to women (15% vs. 12%). In both sexes, case numbers increased steadily over the study period, with a transient decline in 2020. The rise in cases with lung involvement among patients with IRD over time was more pronounced in men. The number of hospitalized patients with lung involvement secondary to IRD has increased continuously over the past 19 years. Male patients with IRD appear to have a higher risk of developing lung involvement compared to female patients.
-
7. [PRiVENT in the selective care contract: Structured care for high-risk patients to prevent long-term invasive ventilation and tracheostomy].
PMID:日期:2026-08-31PRiVENT (Prevention of Invasive Ventilation through Early Identification and Early Intervention in Patients at Risk) is a cross-sectoral care model developed within the framework of the Innovation Fund of the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA). The aim of the project was to identify patients at increased risk of prolonged mechanical ventilation at an early stage and to promote successful weaning from mechanical ventilation through the early involvement of certified weaning centres and structured, interprofessional interventions. By doing so, the project seeks to prevent long-term invasive mechanical ventilation, tracheostomy, and the need for long-term out-of-hospital intensive care.Based on the initial positive results of the Innovation Fund project, a selective integrated care contract pursuant to § 140a of the German Social Code Book V (SGB V) was developed in collaboration with AOK Baden-Württemberg. The objective of this contract was to sustainably transfer the care structures established during the project into routine clinical care and to make them available throughout Baden-Württemberg for insured members of AOK Baden-Württemberg.The core components of the PRiVENT care pathway are the Weaning Board and the Weaning Consultation, both of which are conducted by an interprofessional team consisting of at least a pulmonologist and a respiratory therapist from a certified specialised weaning centre. Consultations may be performed via telemedicine, in a hybrid format, or entirely on site. The following section describes the healthcare services provided within the PRiVENT selective care contract under § 140a SGB V.
-
8. [Is the tobacco industry reinventing itself?]
PMID:日期:2026-08-25The tobacco industry has repeatedly adjusted its product strategy in the past. As soon as the health risks of tobacco use could no longer be denied, it responded with high-profile campaigns designed to downplay scientific findings. In addition, it introduced modified products such as cigarette filters and so-called "light" cigarettes, which give the impression of being less harmful. This strategy has become increasingly less successful in recent years. Public health policies focused on environmental prevention, combined with increased public awareness, have led to a global decline in tobacco consumption. With new nicotine products such as e-cigarettes, tobacco heaters, and nicotine pouches, an additional market segment is now being developed to complement the shrinking core market. And once again, the health risks associated with the mechanism of addiction are downplayed as "harm reduction". New products are redefined as therapeutic aids for smoking cessation, through which the tobacco industry seeks to present itself as a pharmaceutical entity. At the same time, the company will continue to operate in the core market for tobacco products as part of a two-pronged strategy, and this product segment is expected to remain the dominant source of revenue and profit for the foreseeable future. In this respect, the tobacco industry is adapting to the new circumstances without abandoning the business model based on nicotine addiction.
-
9. [80 Years of Lung Cancer - the Evolution of Diagnosis and Treatment].
PMID:日期:2026-08-24Exactly 80 years ago - in April 1946 and in Chicago, the very city where the latest developments in oncology are discussed annually at the ASCO meeting - Thomas Mann, the German Nobel Prize-winning author and chain-smoker, underwent lung surgery. On April 24, 1946, thoracic surgeon Dr. William E. Adams removed the lower and middle lobes of his right lung due to carcinoma at the University of Chicago Hospital; Mann survived the operation without recurrence for nine years before eventually passing away from an aortic aneurysm. What made this surgery remarkable was the limited resection - avoiding the complete removal of the entire lung, which had previously been the only standard treatment for lung carcinoma. Since then, treatment options for lung carcinoma have changed significantly. In the following section, we provide a brief overview of how and what has changed.
-
10. [Giant Chondroid Pulmonary Hamartoma with a Diameter of 10 cm: A Case Report].
PMID:日期:2026-08-21Pulmonary hamartomas are benign, predominantly mesenchymal lung neoplasms that represent the most common benign lung tumors and typically do not exceed 4 cm in diameter. Lesions larger than this size are considered "giant" hamartomas and have been only rarely described in the literature. We report the case of a 62-year-old male patient with dyspnea, in whom a chest X-ray revealed a mass in the right lower lobe. The subsequent computed tomography confirmed a well-circumscribed mass with a maximum diameter of 98 mm. Complementary thoracic MRI showed a heterogeneous mass in the right lower lobe measuring approximately 97 × 87 mm. Sonography over the right intercostal space revealed a solid mass with hypoechoic internal structure; in correlation with the cross-sectional imaging findings, the lesion was most consistent with a hamartoma. Due to the size of the mass and the inability to rule out malignancy, a parenchyma-sparing surgical enucleation was performed. Histopathological examination confirmed the diagnosis of a pulmonary hamartoma of the chondroid type. The postoperative course was uneventful. This case underscores that unusually large intrapulmonary masses can also be of benign nature and highlights the importance of careful radiological and histopathological evaluation prior to therapeutic decision-making.